



Research article

Optimal control and Bayes inference applied to complex microbial communities

Jhoana P. Romero-Leiton^{1,2,*}, **Kernel Prieto**², **Daniela Reyes-Gonzalez**³ and **Ayari Fuentes-Hernandez**³

¹ Engineering Faculty, Cesmag University, Pasto, Colombia

² Design and Visual Arts Department, Georgian College, Barrie, Canada

³ Center for Genomic Sciences, National Autonomous University of Mexico, Cuernavaca, Mexico

* **Correspondence:** Email: jpatirom3@gmail.com, JhoanaPatricia.RomeroLeiton@mygeorgian.ca;
Tel: +14388368866.

Abstract: Interactions between species are essential in ecosystems, but sometimes competition dominates over mutualism. The transition between mutualism-competition can have several implications and consequences, and it has hardly been studied in experimental settings. This work studies the mutualism between cross-feeding bacteria in strains that supply an essential amino acid for their mutualistic partner when both strains are exposed to antimicrobials. When the strains are free of antimicrobials, we found that, depending on the amount of amino acids freely available in the environment, the strains can exhibit extinction, mutualism, or competition. The availability of resources modulates the behavior of both species. When the strains are exposed to antimicrobials, the population dynamics depend on the proportion of bacteria resistant to the antimicrobial, finding that the extinction of both strains is eminent for low levels of the resource. In contrast, competition between both strains continues for high levels of the resource. An optimal control problem was then formulated to reduce the proportion of resistant bacteria, which showed that under cooperation, both strains (sensitive and resistant) are immediately controlled, while under competition, only the density of one of the strains is decreased. In contrast, its mutualist partner with control is increased. Finally, using our experimental data, we did parameters estimation in order to fit our mathematical model to the experimental data.

Keywords: antimicrobials; sensitive bacteria; resistant bacteria; amino acids; cross-feeding bacteria; mutualism; competition; experimental data; parameter estimation

1. Introduction

The rapid surge of resistant strains and the void in discovering of new antimicrobials has made antimicrobial resistance one of the most critical problems in public health nowadays. There has been a great effort from the scientific community to understand the basic mechanisms by which bacteria become resistant to several antibiotics; almost all efforts have focused on the study of a single strain, and it is just in recent times that we have been looking at how the interaction between members of complex communities are shaping the susceptibility profile.

In nature, microbes co-exist in multi-species communities with ecological dynamics driven by the complex interaction between individual strains and the environment. Syntrophic interactions, whereby bacterial cells exchange costly metabolites for the benefit of both interacting partners, are pervasive in bacterial communities as they enhance bacterial survival in hostile environments.

Availability of resources affects the nature of the interactions between members of a microbial consortium [1]. These interactions can be determinants of the stability of the consortia. Based on two-pair interactions, there are typically three outcomes; cooperation where both members of the community are beneficial to the other one; competition where the presence of one member is detrimental to the other one and neutral interaction; where the members of the community have no interaction.

Typically competitive interactions end up in competitive exclusion, decreasing the diversity of the consortia. For syntrophic interactions, if the competition for resources is very strong, one community member's collapse could collapse the total population.

The effect of changes in interactions have on the control of antibiotic resistance is unknown. There are some examples where cooperation can help a community to survive in stressful environments [2]. We model a synthetic community composed of two different strains; both are auxotrophic to an amino acid, an essential metabolite. This condition makes them incapable of growing on their own in an environment without amino acids. In contrast, they can grow in a minimal media when they are together due to the leak of all the other amino acids from their partner [3]. Auxotroph cells are essential for natural communities [4], they shape the composition and can be determinant of the stability of a microbial community. For instance, they have been found in aquatic communities [5], microbial soil communities [6] and the human microbiome [7, 8]. Although auxotrophies could increase the dependence of individuals in the communities, they could also increase fitness by reducing the nutrient requirements of an environment, which means that a community could support growth in a poorer context.

In the past years, auxotrophic strains have been used to study metabolic cross-feeding interactions in particular environmental context [1, 9, 10]. Pair-wise interactions are useful to determine changes in the interaction and to study division of labor inside the community, such as public goods. A relevant example of public goods is the production of enzymes able to degrade antibiotics.

Cross-feeding interactions in natural environments are important to increase diversity in the population by decreasing the fitness of the individual and increasing the fitness of the community [11]. It has been shown that these interactions are dynamic and can change with respect to the environment. Auxotrophies are a particular example of this. It has also been shown that auxotrophic phenotypes appear very fast in a population growing in a rich nutrient environment [10]. This feature can be crucial in diverse communities, like the microbiota, particularly when an

antimicrobial is present, which disrupts the community members [4]. If auxotrophic phenotypes appear, having functional redundancies could help preserve general function in a community. For this reason, understanding what is the effect of an antimicrobial in a syntrophic consortium could be of great value.

This paper explores a population-based model and control theory to understand the effect of antimicrobials in microbial communities with syntrophic interactions and how the environment minimizes resistant bacteria in the system.

We first propose an optimal control problem based on Hoek et al. in [1] of an auxotrophic consortium of two bacteria competing for the same resources in the presence of a gradient of antibiotic. Then we described our experimental data and performed numerical experiments. Finally, using Bayesian Inference, we estimate some interesting mathematical model parameters using our experimental data. Numerical experiments validate all theoretical results.

2. Optimal control formulation

In order to better understand the different types of interaction between cross-feeding bacteria, we formulate a similar mathematical model to the proposed by Hoek et al. In [1], two strains of yeast, one auxotrophic to tryptophan (*trp*-) and the other auxotrophic to leucine (*leu*-) interact in an environment with different resource availability. In this formulation, we assume that strain *trp*- (X) and strain *leu*- (Y) are divided into susceptible and resistant bacteria (X_s , X_r and Y_s , Y_r , respectively). We assume both strains interact with a bacterial infection in an individual's body. We are interested in modeling the dynamics of bacterial resistance acquisition through antimicrobial resistance induced by antibiotic-mediated selection. Thus, the following hypothesis is considered for the strain X (similar assumptions can be considered for the strain Y): sensitive bacteria grows at a rate proportional to resistant bacteria (if a is the growth rate of sensitive bacteria, then $a\bar{\gamma}_x$ is the growth rate of resistant bacteria) following the logistic equation with a carrying capacity K . \bar{F} is the amount of supplemented amino acids, $\bar{\kappa}$ represents an effective Monod constant, and β is a parameter that quantifies the asymmetry of benefit that each bacteria receives from its partner. The density of sensitive bacteria become resistant by antibiotic-mediated selection is given through the term $\epsilon q \lambda X_s$, where ϵ is the efficacy of the antimicrobial, λ is the antimicrobial supply rate, q is the proportion of mutation (therefore $(1-q)$ represents the proportion of elimination). Both population turnover at a constant dilution rate $\bar{\delta}$. Thus, the per capita growth rate of both bacteria is adjusted by the mutualistic partner as well as the supplemented amino acids:

$$\begin{aligned}
 \dot{X}_s &= \bar{\gamma}_x(X_s + X_r) \left(\frac{Y_s + Y_r + \bar{F}}{Y_s + Y_r + \bar{F} + \bar{\kappa}} \right) \left(1 - \frac{X_s + X_r + Y_s + Y_r}{K} \right) - \epsilon q \lambda X_s - \epsilon(1-q)\lambda X_s - \bar{\delta} X_s \\
 \dot{X}_r &= a\bar{\gamma}_x(X_s + X_r) \left(\frac{Y_s + Y_r + \bar{F}}{Y_s + Y_r + \bar{F} + \bar{\kappa}} \right) \left(1 - \frac{X_s + X_r + Y_s + Y_r}{K} \right) + \epsilon q \lambda X_s - \bar{\delta} X_r \\
 \dot{Y}_s &= \bar{\gamma}_y(Y_s + Y_r) \left(\frac{\beta(X_s + X_r) + \bar{F}}{\beta(X_s + X_r) + \bar{F} + \bar{\kappa}} \right) \left(1 - \frac{X_s + X_r + Y_s + Y_r}{K} \right) - \epsilon q \lambda Y_s - \epsilon(1-q)\lambda Y_s - \bar{\delta} Y_s \\
 \dot{Y}_r &= a\bar{\gamma}_y(Y_s + Y_r) \left(\frac{\beta(X_s + X_r) + \bar{F}}{\beta(X_s + X_r) + \bar{F} + \bar{\kappa}} \right) \left(1 - \frac{X_s + X_r + Y_s + Y_r}{K} \right) + \epsilon q \lambda Y_s - \bar{\delta} Y_r.
 \end{aligned} \tag{2.1}$$

A complete description of the parameters involved in Model (2.1) can be found on Table 1.

Table 1. Definition and dimension of the parameters involved in Model (2.1).

Parameter	Definition	Unit
a	Cost of the resistance	Dimensionless
$\bar{\gamma}_x$	Growth rate of strain X	1/time
$\bar{\gamma}_y$	Growth rate of strain Y	1/time
β	Asymmetry constant	Dimensionless
\bar{F}	Amount of supplementary amino acid	Population
$\bar{\kappa}$	Monod constant	Population
ϵ	Antimicrobial efficacy	1/time
λ	Supply concentration of the antimicrobial	Dimensionless
q	Mutation proportion	Dimensionless
$\bar{\delta}$	Dilution rate	1/time
K	Carry capacity	Dimensionless

Now, we define $\boldsymbol{\mu} = (\mu_1(t), \mu_2(t))$ as a control variable associated with the mutations. Thus, both strains of susceptible bacteria mutate at a rate $(1 - \mu_1(t))\epsilon q \lambda X_s$ and $(1 - \mu_2(t))\epsilon q \lambda Y_s$, respectively, where for $i = 1, 2$, $\mu_i(t) \in [0, 1]$ ($\mu_i = 0$ represents no efficacy of the control, while $\mu_i = 1$ indicates that the use of the control is completely effective). Thus, we have that each control variable $\mu_i(t)$ provides information about the amount of bacteria that must not mutate at time t . To minimize the number of resistant bacteria, we define the cost function:

$$J[\boldsymbol{\mu}] = \int_0^T \left(\bar{c}_1 X_r + \bar{c}_2 Y_r + \frac{1}{2} \mu_1(t)^2 + d_2 \frac{1}{2} \mu_2(t)^2 \right) dt,$$

where the parameters c_1 and c_2 represent social cost and the parameters d_1 and d_2 represent relative weights associated to the controls. Additionally, we define the boundary conditions:

$$\mathbf{X}(0) = (X_{s_0}, X_{r_0}, Y_{s_0}, Y_{r_0}) = \mathbf{X}_0$$

$$\mathbf{X}(T) = (X_{s_f}, X_{r_f}, Y_{s_f}, Y_{r_f}) = \mathbf{X}_f,$$

and we assume that the final time T is a fixed implementation time of the control strategies, the final state \mathbf{X}_f is variable, and the initial state \mathbf{X}_0 is a coexistence equilibrium of System (2.1). We suppose that each control is in the set of Lebesgue measurable functions with $0 \leq \mu(t) \leq 1$, $t \in [0, T]$ (\mathcal{U} called the set of admissible controls).

Let us define ω as a rescaling parameter with dimension $1/\text{population} \times \text{time}$. To obtain a dimensionless formulation of System (2.1), the state variables have been divided by the carrying capacity of the environment, the parameters and the time have also been adjusted to be dimensionless as follows

$$S_x = \frac{X_s}{K}, R_x = \frac{X_r}{K}, S_y = \frac{Y_s}{K}, R_y = \frac{Y_r}{K} \text{ and } \tau = \omega K t,$$

and

$$c_1 = \frac{\bar{c}_1}{K}, c_2 = \frac{\bar{c}_2}{K}, F = \frac{\bar{F}}{K}, \kappa = \frac{\bar{\kappa}}{K}, \gamma_x = \frac{\bar{\gamma}_x}{\omega K}, \gamma_y = \frac{\bar{\gamma}_y}{\omega K}, c = \frac{\epsilon \lambda}{\omega K} \text{ and } \delta = \frac{\bar{\delta}}{\omega K}.$$

Thus, our optimal control problem can be written in the following dimensionless form

$$\left\{ \begin{array}{l} \min J[\boldsymbol{\mu}] = \int_0^T \left(c_1 R_x + c_2 R_y + d_1 \frac{1}{2} \mu_1(t)^2 + d_2 \frac{1}{2} \mu_2(t)^2 \right) dt \\ \frac{dS_x}{d\tau} = \gamma_x (S_x + R_x) \left(\frac{S_y + R_y + F}{S_y + R_y + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] - (1 - \mu_1(t)) q c S_x - (1 - q) c S_x - \delta S_x \\ \frac{dR_x}{d\tau} = a \gamma_x (S_x + R_x) \left(\frac{S_y + R_y + F}{S_y + R_y + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] + (1 - \mu_1(t)) q c S_x - \delta R_x \\ \frac{dS_y}{d\tau} = \gamma_y (S_y + R_y) \left(\frac{\beta(S_x + R_x) + F}{\beta(S_x + R_x) + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] - (1 - \mu_2(t)) q c S_y - (1 - q) c S_y - \delta S_y \\ \frac{dR_y}{d\tau} = a \gamma_y (S_y + R_y) \left(\frac{\beta(S_x + R_x) + F}{\beta(S_x + R_x) + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] + (1 - \mu_2(t)) q c S_y - \delta R_y \\ \mathbf{X}(0) = (S_{x_0}, R_{x_0}, S_{y_0}, R_{y_0}) = \mathbf{X}_0 \\ \mathbf{X}(T) = (S_{x_f}, R_{x_f}, S_{y_f}, R_{y_f}) = \mathbf{X}_f. \end{array} \right. \quad (2.2)$$

2.1. Theoretical results

Let us set as $\mathbf{X} = (S_x, R_x, S_y, R_y)$ the vector of states, $\mathbf{Z} = (z_1, z_2, z_3, z_4)$ the vector of adjoint variables and $f_0(t, \mathbf{X}, \boldsymbol{\mu})$ the integrand of the cost function. We will use the Pontryagin principle for bounded controls to compute the optimal control of Problem (2.2). First of all, following the classical results given in the references [12, 13] it is easy to verify the existence of optimal controls (it is enough to check that the properties (i)–(iii) of Section 3.4 from reference [14] are fulfilled). Now, the Hamiltonian H associated with the Problem (2.2) is defined by $H(t, \mathbf{X}(t), \boldsymbol{\mu}(t), \mathbf{Z}(t)) = f_0(t, \mathbf{X}, \boldsymbol{\mu}) + \mathbf{Z}(t) \cdot f(\mathbf{X}, t, \boldsymbol{\mu})$, that is

$$\begin{aligned} H = & c_1 R_x + c_2 R_y + d_1 \frac{1}{2} \mu_1^2 + d_2 \frac{1}{2} \mu_2^2 + \\ & z_1 \left[\gamma_x (S_x + R_x) \left(\frac{S_y + R_y + F}{S_y + R_y + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] - (1 - \mu_1) q c S_x - (1 - q) c S_x - \delta S_x \right] + \\ & z_2 \left[a \gamma_x (S_x + R_x) \left(\frac{S_y + R_y + F}{S_y + R_y + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] + (1 - \mu_1) q c S_x - \delta R_x \right] + \\ & z_3 \left[\gamma_y (S_y + R_y) \left(\frac{\beta(S_x + R_x) + F}{\beta(S_x + R_x) + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] - (1 - \mu_2) q c S_y - (1 - q) c S_y - \delta S_y \right] + \\ & z_4 \left[a \gamma_y (S_y + R_y) \left(\frac{\beta(S_x + R_x) + F}{\beta(S_x + R_x) + F + \kappa} \right) \left[1 - (S_x + R_x + S_y + R_y) \right] + (1 - \mu_2) q c S_y - \delta R_y \right]. \end{aligned} \quad (2.3)$$

The adjoint system and state equations define the optimal system. The following theorem summarizes the main result of this section.

Theorem 2.1. *There is an optimal solution $X^*(t)$ that minimize $J[\mu]$ in $[0, T]$. Moreover, there exists a vector of adjoint variables Z such that*

$$\begin{aligned} \dot{z}_1 = & \gamma_x \left(\frac{(S_y + R_y + F)(-1 + 2S_x + S_y + 2R_x + R_y)}{(S_y + R_y + F + \kappa)} \right) (z_1 + az_2)c \\ & + \gamma_y \left(\frac{F^2 + F\kappa - \beta\kappa + \beta(\beta R_x^2 + \kappa R_y + 2R_x(F + \kappa + \beta S_x))}{(\beta(S_x + R_x) + F + \kappa)^2} \right) (z_3 + az_4) \\ & + \gamma_y \left(\frac{S_x(2(F + \kappa) + \beta S_x) + \kappa S_y)(S_y + R_y)}{(\beta(S_x + R_x) + F + \kappa)^2} \right) (z_3 + az_4) \\ & + cq\mu_1(z_2 - z_1) - c(qz_2 - z_1) + \delta z_1 \\ \dot{z}_2 = & \gamma_x \left(\frac{(S_y + R_y + F)(-1 + 2S_x + S_y + 2R_x + R_y)}{(S_y + R_y + F + \kappa)} \right) (z_1 + az_2) \\ & + \gamma_y \left(\frac{F^2 + F\kappa - \beta\kappa + \beta(\beta R_x^2 + \kappa R_y + 2R_x(F + \kappa + \beta S_x))}{(\beta(S_x + R_x) + F + \kappa)^2} \right) (z_3 + az_4) \\ & + \gamma_y \left(\frac{S_x(2(F + \kappa) + \beta S_x) + \kappa S_y)(S_y + R_y)}{(\beta(S_x + R_x) + F + \kappa)^2} \right) (z_3 + az_4) \\ & - c_1 + \delta z_2 \\ \dot{z}_3 = & \gamma_y \left(\frac{(\beta(S_x + R_x) + F)(-1 + S_x + 2S_y + R_x + 2R_y)}{(\beta(S_x + R_x) + F + \kappa)} \right) (z_3 + az_4) \\ & + \gamma_x \left(\frac{F^2 + (-1 + F)\kappa + \kappa R_x + R_y^2 + \kappa S_x + 2(F + \kappa)S_y}{(S_y + R_y + F + \kappa)^2} \right) (z_1 + az_2) \\ & + \gamma_x \left(\frac{S_y^2 + 2R_y(F + \kappa + S_y)(S_y + R_y)}{(S_y + R_y + F + \kappa)^2} \right) (z_1 + az_2) \\ & + cq\mu_2(z_4 - z_3) - c(qz_4 - z_3) + \delta z_3 \\ \dot{z}_4 = & \gamma_y \left(\frac{(\beta(S_x + R_x) + F)(-1 + S_x + 2S_y + R_x + 2R_y)}{(\beta(S_x + R_x) + F + \kappa)} \right) (z_3 + az_4) \end{aligned}$$

$$\begin{aligned}
& + \gamma_x \left(\frac{F^2 + (-1 + F)\kappa + \kappa R_x + R_y^2 + \kappa S_x + 2(F + \kappa)S_y}{(S_y + R_y + F + \kappa)^2} \right) (z_1 + az_2) \\
& + \gamma_x \left(\frac{S_y^2 + 2R_y(F + \kappa + S_y)(S_y + R_y)}{(S_y + R_y + F + \kappa)^2} \right) (z_1 + az_2) \\
& - c_2 + \delta z_4,
\end{aligned} \tag{2.4}$$

with transversality condition $z_i(t) = 0$ for $i = 1, 2, 3, 4$ which satisfies:

$$\begin{aligned}
\mu_1^* &= \frac{qcS_x(z_2 - z_1)}{d_1} \\
\mu_2^* &= \frac{qcS_y(z_4 - z_3)}{d_2}.
\end{aligned} \tag{2.5}$$

To see a detailed proof of the previous theorem see Appendix A.

3. Experimental data

We used *Escherichia coli* strains from the Keio collection containing either $\Delta ilvA$ or $\Delta tyrA$ deletions [15], each strain was transformed with the plasmid pBGT-1 [16] carrying blaTEM-1 gene that confers resistance to ampicillin and a GFP fluorescent marker inducible with arabinose, pBGT-1 is a non-conjugative plasmid with around 20 copies in average per cell. Strains were grown in LB medium (Lysogeny Broth) with 40 $\mu\text{g}/\text{mL}$ of kanamycin and 100 $\mu\text{g}/\text{mL}$ of ampicillin (for those with plasmid) at 30°C for 16 hours after incubation strains were washed with M9 salts and re-suspended in M9 minimal medium supplemented with glucose.

To measure susceptibility to the antimicrobial, we performed dose-response experiments in 96-well plates. The ampicillin concentrations used were 0, 6, 15, 36, 89, 220, 540, 1326, 3257 and 8000 $\mu\text{g}/\text{mL}$, each well was inoculated with 20 μL of clean cells for a total of 200 μL per well and incubated in an ELx808 plate reader at 30°C with continuous shaking, OD630 was measured every 20 minutes for 24 hours, data not shown.

Co-cultures were performed in 96-well plates with 180 μL of LB media with 6 $\mu\text{g}/\text{mL}$ of ampicillin, and 20 μL of cells with 80% of susceptible cells ($\Delta ilvA$ or $\Delta tyrA$) and 20% of resistant cells ($\Delta tyrA$ -pBGT or $\Delta ilvA$ -pBGT). Two equal plates were grown in a ELx808 plate reader at 30°C with eight replicates for condition in each plate, OD630 was measured every 20 minutes for 24 hours, one plate was used for growth rate analysis, and the second one was used to measure colony forming units (CFU), relative abundance and cell viability, every 2 hours we collected one of the replicates of the second plate and divided the sample, as we had to open the well, this procedure was destructive to the sample, to have sampled every 2 hours, we completely used one of the plates, the other one was kept in the plate reader.

For relative abundance and cell viability, one replicate was collected every 2 hours and supplemented with 20 μL of arabinose (0.5%), incubated at 30°C for 4 hours, and stored at 4°C for

one day to induce GFP fluorescence. After storage, 100 μL of each sample was frozen, 5 μL from a 1:1000 dilution were incubated for 2 days at 30°C in selective agar with M9 minimal media, supplemented with 10.9 mg/L isoleucine and 7.15 mg/L tyrosine and 0.5% of arabinose for CFU counting, the rest of the sample was used to measured abundance of resistant cells using a CytoFLEX S cytometer (20,000 events per sample).

For experimental data, we performed 16 replicas in total, 8 were kept at a plate reader to measure OD shown in Figure 1A, the other eight replicas were used to measured abundance of cells and viability, the experimental data measured in the flux cytometer every 2 hours splitting resistance and susceptible bacteria are shown in Figure 1B.




Figure 1. Experimental data from co-cultures of cells with 80% of susceptible cells ($\Delta ilvA$ or $\Delta tyrA$) and 20% of resistant cells ($\Delta tyrA$ -pBGT or $\Delta ilvA$ -pBGT) grown in LB media with 6 $\mu\text{g}/\text{ml}$ of ampicillin (low concentration). In **A** we showed the optical density of eight replicas of the co-culture in 24 hours, solid line represent the average of the 8 replicas and shadows showed standard error for each data point, measurements taken every 20 minutes. **B** shows the frequency of susceptible and resistant bacteria, dots represents data point every 2 hours measured in the flux cytometer, all data processed with Matlab.

4. Numerical simulations

In order to performed the optimal control numerical experiments, we used the *Backward-Forward Sweep Method* described on Lenhart et al. [13] in Matlab interface, and also we used our experimental data given in Section 3 and some data collected in the reference [1], from two non-mating budding yeast strains of *Saccharomyces cerevisiae* that were designed to be deficient in the biosynthesis of an essential amino acid and also to overproduce the amino acid required by the ir partner. In such

laboratory experiments, the auxotrophic strain of leucine (*leu-*) overproduces tryptophan, while the auxotrophic strain of tryptophan (*trp-*) overproduces leucine. According to reference [1], these strains have previously been shown to form a cross-feeding mutualism when grown on solid agar, with each strain losing the amino acid needed by its partner. We assume that the carrying capacity $K = 0.1 \times 10^6$ and the temporal value is $\omega = 0.3 \times 10^{-5}$. The values of the other parameters taken in this study are given in Table 2.

Table 2. Values of the parameters involved in Models (2.1) and (2.2). Some of them were taken from the reference [1], whereas other from our experimental data.

Parameter	Dimensional model	Dimensionless model
Growth rate of bacteria X	0.3	1
Growth rate of bacteria Y	0.288	0.96
Asymmetry constant	2	2
Dilution rate	0.15	0.5
Monod constant	12,000	0.12
Cost of resistance	0.01	0.01
Antimicrobial concentration	$\lambda = 10$	$c = 16.67$
Antimicrobial efficacy	$\epsilon = 0.5$	

In these experiments we consider that the amount of supplementary amino acids and the proportion of mutations are variables. The mutation portion (q) values used were 0.1, 0.5 and 0.9, parameters for the amount of amino acids used are shown in Table 3.

Table 3. Values for the amount of supplementary amino acids.

Dimensional model (\bar{F})	Dimensionless model (F)
1000	0.01
5000	0.05
150,000	1.5

In Figure 2 we show some numerical experiments of sensitive bacteria (X and Y) of Model (2.2), when there are no antimicrobials, for different values of F . From this figure, we can see that when F is small enough ($F = 0.01$) there is the extinction of both strains. When F grows ($F = 0.05$) there is cooperation or mutualism between both strains, whereas, for large values of F (1.5), there is competition between both strains, being evident in the increase in the strain X and the extinction of the strain Y .




Figure 2. Simulations of sensitive strains X and Y of Model (2.2), when there are no antimicrobials, for different values of supplementary amino acids (F). When F is small, there is extinction, when F grows, there is mutualism, whereas, for large values of F , there is competition.

In Figure 3, we supply antimicrobials in our system, we keep fixed the value of $F = 0.01$ (where the is the extinction of both bacteria), and vary the values of the mutation proportion q (0.1, 0.5 and 0.9). In this case, we can see that the sensitive strains tend to zero regardless of the value of q , whereas for large values of q , the resistant bacteria of both types (X and Y) increase in density at the beginning of the time.




Figure 3. Simulations of the state equations of Model (2.2) for $F = 0.01$ and different values of q . Here, the sensitive strains tend to zero regardless of the value of q , whereas for large values of q , the resistant bacteria of both phenotypes increase in density at the beginning of the time.

A different scenario occurs for $F = 0.05$ (where there is cooperation between both strains), which can be evident in Figure 4. Here we can see that both strains become extinct only for small values of q ($q = 0.5$ or less), while if q increases (0.9), they coexist in density over time.




Figure 4. Simulations of the state equations of Model (2.2) for $F = 0.05$ and different values of q . Here, both strains become extinct only for small values of q ($q = 0.5$ or less), while if q increases, they coexist in density over time.

Finally, for $F = 1.5$ (see Figure 5), we can see that the strain Y decreases no matter what value of q is taken. On the other hand, the strain X stabilizes at increasing densities as the value of q changes.




Figure 5. Simulations of the state equations of Model (2.2) for $F = 1.5$ and different values of q . The strain Y decreases no matter what value of q is taken. The strain X stabilizes at increasing densities as the value of q changes.

To observe the effect of controlling the antimicrobial resistance in the system where the strains X and Y interact in an environment with antimicrobials, we use the *Forward-Backward Sweep Method* proposed by Lenhart and Workman [13]. The values of the parameters associated with Problem (2.2) are shown in Table 4. We only introduce the control variables for the cases where there is a high

proportion of mutation ($q = 0.9$) and for the mutualism ($F = 0.05$) and competition ($F = 1.5$). In Figure 6 we show the results of control when $F = 0.05$ and $q = 0.9$ (where there is cooperation). In this case, with controls, both populations of bacteria are controlled immediately, maintaining the two controls at their maximum effort during the first 40 days and then rapidly decreasing to zero during the rest of the control campaign. In Figure 8 we show the results when $F = 1.5$ and $q = 0.9$ (when there is competition). Here, it can be seen that only the strain X is controlled from the first day of the campaign. But the strain Y increases with the control. The effort is only made for the first control at 100%, while the second control remains at zero throughout the campaign.




Figure 6. Simulations of the Optimal Control (2.2) under mutualism ($F = 0.05$ and $q = 0.9$). With controls, both bacteria are controlled immediately.

Table 4. Values of the parameters associated with the optimal control problem (2.2).

	Parameter	Value
Weights	d_1	0.0001
	d_2	0.0001
Social costs	c_1	0.001
	c_2	0.001




Figure 7. Simulations of the Optimal Control (2.2) under competition ($F = 1.5$ and $q = 0.9$). Only the strain X is controlled from the first day of the campaign. But the strain Y increases with the control.




Figure 8. Simulations of the Optimal Control (2.2) under competition ($F = 1.5$ and $q = 0.9$). Only the strain X is controlled from the first day of the campaign. But the strain Y increases with the control.

5. Parameter estimation

For the parameter estimation of Model (2.1) we used the experimental data described in Section 3. To simplify notation, we will drop the bar symbol on the parameters from here. The experimental data is shown in Figure 9. Since the data size is very low, i.e., we have just six point for each time series of type of bacteria, we have implemented a re-sample with an interpolation for the values of odd hours in order to increase the data size. Specifically, we used a rich media called LB, and low ampicillin concentration. The values are described in Table 5.




Figure 9. Experimental data: a rich media (LB) and low ampicillin concentration.

The fitting curve or estimation of the parameters of a model is considered an inverse problem. Some references of works using Bayesian inference are available in references [17–21]. Let $F : \mathbb{R}^m \rightarrow \mathbb{R}^{s \times k}$, denoted by $F(\theta)$ be the forward problem, where θ are the parameters of Model (2.1) to estimate, m the number of parameter to estimate, and k the number of state variables. The inverse problem is formulated as a standard optimization problem

$$\min_{\theta \in \mathbb{R}^m} \|F(\theta) - y_{\text{obs}}\|^2, \quad (5.1)$$

with y_{obs} . Given $y_{\text{obs}} = (\tilde{I}, \tilde{A})$, which correspond to strain *tyrA*- (X) and strain *ilvA*- (Y) are divided into susceptible and resistant bacteria (X_s, X_r and Y_s, Y_r , respectively), the conditional probability distribution $\pi(\theta|y_{\text{obs}})$, called the posterior distribution of θ is given by the Bayes' theorem:

$$\pi(\theta|y_{\text{obs}}) \propto \pi(y_{\text{obs}}|\theta)\pi(\theta). \quad (5.2)$$

All the available information regarding the unknown parameter θ is codified into the prior distribution $\pi(\theta)$, which specifies our belief in a parameter before observing the data. All the available information regarding the way of how was obtained the measured data is codified into the likelihood distribution $\pi(y_{\text{obs}}|\theta)$. This likelihood can be seen as an objective or cost function, as it punishes deviations of the model from the data. A Poisson distribution, $\mathcal{P}(y|\mu)$, with respect to the time, is typically used to account for the discrete nature of these counts, where μ is the mean of the random variable y , i.e., $\mathbb{E}[Y] = \mu$. We assume independent Poisson distributed noise η , i.e., all dependency in the data is codified into the model (2.1). In other words, the positive definite noise covariance matrix η is assumed to be diagonal. The posterior distribution $\pi(\theta|y_{\text{obs}})$ given by (5.2) does not have an analytical closed form since the likelihood function, which depends on the solution of the non-linear model (2.1), does not have an explicit solution. Then, we explore the posterior distribution using the Stan Statistics package [22]. We have used the Automatic Differentiation Variational Inference method (ADVI), which is based on the automatic variational inference algorithm. Specifically, we have used the Full-Rank submethod of ADVI. We have used the interface in Python (PyStan) [22], for more details see this Github link. Table 5 shows the posterior mean, quantiles of all estimated parameters of model (2.1). Table 6 shows the prior distributions summary of the estimated parameters of Model (2.1) using the experiment data set. Gamma distributions were used for parameters $\kappa, \gamma_x, \gamma_y$ and q . Uniform distribution were used for the initial conditions $S_{x_0}, R_{x_0}, S_{y_0}, R_{y_0}$. Figure 11 shows the joint probability density distributions of the estimated parameters within 95% (HPD) using the experimental data. The blue lines represent the medians. Figure 12 shows Model fit for sensitive and resistant bacteria of Model (2.1) using the experiment data. Blue and red dot points represent strain *ilvA* (X) data, i.e., the susceptible and resistant bacteria, called S_x and R_x , respectively. Orange and purple solid lines represent the median of posterior distribution of the sensitive and resistant bacteria (*ilvA-pBGT* (X)), respectively. Shaded area represent the 95% probability bands for the expected value of sensitive (orange line), resistant bacteria (blue line). Figure 13 shows Model fit for sensitive and resistant bacteria of the model (2.1) using the experiment data. Blue and red dot points represent strain *tyrA* (Y) data, i.e., the susceptible and resistant bacteria, called S_y and R_y , respectively. Orange and purple solid lines represent the median of the posterior distribution of the sensitive and resistant bacteria strain *tyrA-pBGT* (Y), respectively. Shaded area represent the 95% probability bands for the expected value of sensitive (orange line), resistant bacteria (blue line).

Table 5. Posterior mean and quantiles of all the estimated parameters of Model (2.1) using the experimental data described in Section 3.

Parameter	Mean	Std	Min	25%	50%	75%
κ	6332296.7333	107726.2128	5970880.0000	6257630.0000	6332720.0000	6407300.0000
γ_x	7.4709	0.0481	7.3150	7.4371	7.4713	7.5055
γ_y	5.9583	0.0909	5.6493	5.9035	5.9557	6.0205
q	0.0199	0.0008	0.0175	0.0194	0.0199	0.0205

Table 6. Prior distributions summary of the estimated parameters of model (2.1) using the experiment data set. Gamma distributions were used for parameters κ , γ_x , γ_y and q . Uniform distribution were used for the initial conditions S_{x_0} , R_{x_0} , S_{y_0} , R_{y_0} .

Parameter	Support	Prior distribution
κ	$[5 \times 10^3, 5 \times 10^7]$	Gamma, $a = 2.5, b = 1$
γ_x	$[0, 10]$	Gamma, $a = 2.5, b = 1$
γ_y	$[0, 10]$	Gamma, $a = 2.5, b = 1$
q	$[0, 0.2]$	Gamma, $a = 2.5, b = 1$
S_{x_0}	$[1 \times 10^5, 5 \times 10^7]$	Uniform
R_{x_0}	$[1 \times 10^5, 5 \times 10^7]$	Uniform
S_{y_0}	$[1 \times 10^5, 5 \times 10^7]$	Uniform
R_{y_0}	$[1 \times 10^5, 5 \times 10^7]$	Uniform




Figure 10. Credible intervals of the parameters of the model (2.1) within 95% Highest-Posterior-Density (HPD).




Figure 11. Joint probability density distributions of the estimated parameters within 95% (HPD) using the experimental data. The blue lines represent the medians.




Figure 12. Model fit for sensitive and resistant bacteria of Model (2.1) using the experiment data. Blue and red dot points represent strain *ilvA* (X) data, i.e., the susceptible and resistant bacteria, called S_x and R_x , respectively. Orange and purple solid lines represent the median of the posterior distribution of the sensitive and resistant bacteria (*ilvA-pBGT* (X), respectively. Shaded area represent the 95% probability bands for the expected value of sensitive (orange line), resistant bacteria (blue line).




Figure 13. Model fit for sensitive and resistant bacteria of the model (2.1) using the experiment data. Blue and red dot points represent strain *tyrA* (Y) data, i.e., the susceptible and resistant bacteria, called S_y and R_y , respectively. Orange and purple solid lines represent the median of the posterior distribution of the sensitive and resistant bacteria strain *tyrA-pBGT* (Y), respectively. Shaded area represent the 95% probability bands for the expected value of sensitive (orange line), resistant bacteria (blue line).

6. Discussion

In this work, we attempted to explain the ecological interactions between cross-feeding bacteria in strains that supply an essential amino acid for their mutualistic partner when they are exposed to antimicrobials. Although from the ecological point of view, the microbial interaction can occur between multiple bacteria, for illustration and ease of handling mathematical equations, we considered the interaction between two bacteria. We formulated a mathematical model using ODEs assuming that both strains interact in an environment with different resources availability. We assumed both strains are divided into susceptible and resistant. After that, we estimated the most important parameters of the ODEs model using Bayesian Inference.

To validate our theoretical results with numerical experiments, we used our experimental data and other data available in the literature. More specifically, we used *Escherichia coli* strains from the Keio collection containing either $\Delta ilvA$ or $\Delta tyrA$ deletions, where each strain was transformed with a plasmid that confers resistance to ampicillin. For some parameters, we also used data from Hoek et al. in [1] of auxotrophic consortia of two microbes competing for the same resources.

The theoretical and numerical results showed that when the strains are free of the antimicrobial, depending on the amount of amino acids freely available in the environment, the strains can exhibit extinction, mutualism, or competition, the availability of resources modulates the behavior of both species. In contrast, if the strains are exposed to antimicrobials, the population dynamics depends on the proportion of bacteria that presents resistance to the antimicrobial, finding that for low levels of the resource, the two species become extinct, whereas, for high levels of the resource, competition between both strains is given.

The optimal control results showed that both strains (sensitive and resistant) are immediately controlled under cooperation, while under competition, only the density of one of the strains decreases, whereas its mutualist partner with control increases. Finally, the growth rates of both strains ($\bar{\gamma}_x$ and $\bar{\gamma}_y$), the Monod constant ($\bar{\kappa}$) the mutation proportion (q) and the initial conditions of Model (2.1) were estimated using Bayesian Inference and the data set described in Section 3. From Figures 12 and 13, we could observe that the fitting is not entirely accurate. This could be due to the lack of data and/or also because Model (2.1) should be adjusted.

The results obtained with this study corroborated that the antimicrobial resistance phenomenon is a complex problem worldwide that the scientific community has extensively studied. This problem is not only related to biological aspects of microorganisms but also other aspects, including socioeconomic and governance factors of countries [23]. Even, some authors claim that a novel approach to antibiotic discovery would be based on the analysis of microbial consortia in their ecological context (see [24, 25]). Others discuss the potential of microbial interactions to target and improve microbial dysbiosis as a strategy for the prevention or treatment of cancer [26]. Additionally, some of them affirm that exposure to sublethal concentrations of antimicrobials can indeed alter microbial metabolism and even change the behavior in beneficial ways, triggering reactions such as fleeing or hiding within the protective environment of a microbial aggregate [27].

Therefore, research questions are left open. A fundamental challenge will be to generate more laboratory experiments to obtain more data to allow better adjustments to the model, and probably adjust the model assuming additional hypotheses.

Acknowledgements

J. Romero thanks the support of Fundación Ceiba, Colombia. We thank A. San Millan for the plasmid p-BGT. D. Reyes-Gonzalez is a doctoral student in Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, and received fellowship 572373 from CONACYT. A. Fuentes-Hernandez was funded by PAPIIT-UNAM (grant IN215920).

Conflict of interest

No potential conflict of interest was reported by the authors.

References

1. T. A. Hoek, K. Axelrod, T. Biancalani, E. A. Yurtsev, J. Liu, J. Gore, Resource availability modulates the cooperative and competitive nature of a microbial cross-feeding mutualism, *PLoS Biol.*, **14** (2016), e1002540. <https://doi.org/10.1371/journal.pbio.1002540>
2. E. Toby Kiers, T. M. Palmer, A. R. Ives, J. F. Bruno, J. L. Bronstein, Mutualisms in a changing world: an evolutionary perspective, *Ecol. Lett.*, **13** (2010), 1459–1474. <https://doi.org/10.1111/j.1461-0248.2010.01538.x>
3. A. R. Figueiredo, R. Kümmerli, Microbial mutualism: Will you still need me, will you still feed me?, *Curr. Biol.*, **30** (2020), R1041–R1043. <https://doi.org/10.1016/j.cub.2020.07.002>
4. K. Zengler, L. S. Zaramela, The social network of microorganisms - how auxotrophies shape complex communities, *Nat. Rev. Microbiol.*, **16** (2018), 383–390. <https://doi.org/10.1038/s41579-018-0004-5>
5. W. M. Johnson, H. Alexander, R. L. Bier, D. R. Miller, M. E. Muscarella, K. J. Pitz, et al., Auxotrophic interactions: a stabilizing attribute of aquatic microbial communities?, *FEMS Microbiol. Ecol.*, **96** (2020), fiae115. <https://doi.org/10.1093/femsec/fiae115>
6. X. Jiang, C. Zerfaß, S. Feng, R. Eichmann, M. Asally, P. Schäfer, et al., Impact of spatial organization on a novel auxotrophic interaction among soil microbes, *ISME J.*, **12** (2018), 1443–1456. <https://doi.org/10.1038/s41396-018-0095-z>
7. X. Zhu, S. Campanaro, L. Treu, R. Seshadri, N. Ivanova, P. G. Kougias, et al., Metabolic dependencies govern microbial syntrophies during methanogenesis in an anaerobic digestion ecosystem, *Microbiome*, **8** (2020), 22. <https://doi.org/10.1186/s40168-019-0780-9>
8. A. E. Douglas, The microbial exometabolome: ecological resource and architect of microbial communities, *Philos. Trans. R. Soc. Lond. B Biol. Sci.*, **375** (2020), 20190250. <https://doi.org/10.1098/rstb.2019.0250>
9. A. Dal Co, C. Brannon, M. Ackermann, Division of labor in bacteria, *Elife*, **7** (2018), e38578. <https://doi.org/10.7554/eLife.38578>
10. G. D'Souza, C. Kost, Experimental evolution of metabolic dependency in bacteria, *PLoS Genet.*, **12** (2016), e1006364. <https://doi.org/10.1371/journal.pgen.1006364>

11. M. A. Henson, P. Phalak, Suboptimal community growth mediated through metabolite crossfeeding promotes species diversity in the gut microbiota, *PLoS Comput. Biol.*, **14** (2018), e1006558. <https://doi.org/10.1371/journal.pcbi.1006558>
12. W. H. Fleming, R. W. Rishel, *Deterministic and stochastic optimal control*, Springer Science and Business Media, 2012.
13. S. Lenhart, J. T. Workman, *Optimal control applied to biological models*, Chapman and Hall/CRC, 2007.
14. H. Mena, L. M. Pfurtscheller, J. P. Romero-Leiton, Random perturbations in a mathematical model of bacterial resistance: Analysis and optimal control, *Math. Biosci. Eng.*, **17** (2020), 4477–4499, <https://doi.org/10.3934/mbe.2020247>
15. T. Baba, T. Ara, M. Hasegawa, Y. Takai, Y. Okumura, M. Baba, et al., Construction of escherichia coli k-12 in-frame, single-gene knockout mutants: the keio collection, *Mol. Syst. Biol.*, **2**, <https://doi.org/10.1038/msb4100050>
16. A. San Millan, J. A. Escudero, D. R. Gifford, D. Mazel, R. C. MacLean, Multicopy plasmids potentiate the evolution of antibiotic resistance in bacteria, *Nat. Ecol. Evol.*, **1** (2016), 1–8. <https://doi.org/10.1038/s41559-016-0010>
17. O. Stojanović, J. Leugering, G. Pipa, S. Ghozzi, A. Ullrich, A Bayesian Monte Carlo approach for predicting the spread of infectious diseases, *PLoS ONE*, **14** (2019), e0225838. <https://doi.org/10.1371/journal.pone.0225838>
18. T. Luzyanina, G. Bocharov, Markov chain Monte Carlo parameter estimation of the ODE compartmental cell growth model, *Math. Biol. Bioinform.*, **13** (2018), 376–391.
19. G. Brown, A. Porter, J. Oleson, J. Hinman, Approximate Bayesian computation for spatial SEIR(S) epidemic models, *Spat. Spatiotemporal Epidemiology*, **24** (2018), 2685–2697, <https://doi.org/10.1016/j.sste.2017.11.001>
20. E. Ibarguen-Mondragon, K. Prieto, S. Hidalgo-Bonilla, A model on bacterial resistance considering a generalized law of mass action for plasmid replication, *J. Biol. Syst.*, **29** (2021), 375–412. <https://doi.org/10.1142/S0218339021400118>
21. K. Prieto, J. P. Romero–Leiton, Current forecast of HIV/AIDS using Bayesian inference, *Nat. Resour. Model.*, **34** (2021), e12332, <https://doi.org/10.1111/nrm.12332>
22. B. Carpenter, A. Gelman, D. Hoffman, B. Goodrich, M. Betancourt, M. Brubaker, et al., Stan: A probabilistic programming language, *J. Stat. Softw.*, **76** (2017), 1–32. <https://doi.org/10.18637/jss.v076.i01>
23. J. Riaño-Moreno, J. P. Romero-Leiton, K. Prieto, Contribution of governance and socioeconomic factors to the *P. aeruginosa* MDR in Europe, *Antibiotics*, **11** (2022), 212. <https://doi.org/10.3390/antibiotics11020212>
24. T. Netzker, M. Flak, M. K. Krespach, M. C. Stroe, J. Weber, V. Schroeckh, et al., Microbial interactions trigger the production of antibiotics, *Curr. Opin. Microbiol.*, **45** (2018), 117–123. <https://doi.org/10.1016/j.mib.2018.04.002>
25. C. Zhang, P. D. Straight, Antibiotic discovery through microbial interactions, *Curr. Opin. Microbiol.*, **51** (2019), 64–71, <https://doi.org/10.1016/j.mib.2019.06.006>

-
26. T. Van Raay, E. Allen-Vercoe, Microbial interactions and interventions in colorectal cancer, *Microbiol. Spectr.*, **5** (2017). <https://doi.org/10.1128/microbiolspec.BAD-0004-2016>
 27. W. C. Ratcliff, R. F. Denison, Alternative actions for antibiotics, *Science*, **332** (2011), 547–548. <https://doi.org/10.1126/science.1205970>

Appendix A. Proof of Theorem 2.1

By the Pontryagin principle, we can guarantee the existence of adjoint variables z_i , $i = 1, 2, 3, 4$ that satisfy:

$$\begin{aligned} \dot{z}_i &= \frac{dz_i}{dt} = -\frac{\partial H}{\partial x_i} \\ z_i(T) &= 0, \quad i = 1, 2, 3, 4 \\ H(\mathbf{X}(t), \boldsymbol{\mu}^*(t), \mathbf{Z}(t), t) &= \max_{\boldsymbol{\mu} \in \mathcal{U}} H(\mathbf{X}(t), \boldsymbol{\mu}(t), \mathbf{Z}(t), t). \end{aligned}$$

From above, the adjoint system can be written as:

$$\begin{aligned} \dot{z}_1 &= -\frac{\partial H}{\partial S_x}, \quad z_1(T) = 0 & \dot{z}_3 &= -\frac{\partial H}{\partial S_y}, \quad z_3(T) = 0 \\ \dot{z}_2 &= -\frac{\partial H}{\partial R_x}, \quad z_2(T) = 0 & \dot{z}_4 &= -\frac{\partial H}{\partial R_y}, \quad z_4(T) = 0. \end{aligned}$$

By doing the respective calculations in the previous equations, we obtain System (2.4). Now, the optimality condition for the Hamiltonian is $\partial H / \partial \boldsymbol{\mu}^*$, or equivalently:

$$\begin{aligned} \frac{dH}{d\mu_1} &= qcS_x(z_1 - z_2) + d_1\mu_1 \\ \frac{dH}{d\mu_2} &= qcS_y(z_3 - z_4) + d_2\mu_2. \end{aligned}$$

From the above, we obtain the characterization given on (2.5). In consequence, μ_1^* satisfies:

$$\mu_1^* = \begin{cases} 1 & \text{if } \frac{qcS_x(z_2 - z_1)}{d_1} > 0 \\ \frac{qcS_x(z_2 - z_1)}{d_1} & \text{if } \frac{qcS_x(z_2 - z_1)}{d_1} \leq 1 \\ 0 & \text{if } \frac{qcS_x(z_2 - z_1)}{d_1} < 0, \end{cases}$$

or equivalently:

$$\mu_1^* = \min \left\{ \max \left\{ 0, \frac{qcS_x(z_2 - z_1)}{d_1} \right\}, 1 \right\}.$$

Similar calculations can be done for μ_2 , and then we obtain the characterization given on Eq (2.5) which completes the proof.



AIMS Press

©2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)